Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-17-008478
Filing Date
2017-08-09
Accepted
2017-08-09 17:17:49
Documents
51
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a30062017rasna10-qq1.htm 10-Q 585151
2 EXHIBIT 31.1 a06302017rasnaexhibit311.htm EX-31.1 14034
3 EXHIBIT 31.2 a06302017rasnaexhibit312.htm EX-31.2 13484
4 EXHIBIT 32.1 a06302017rasnaexhibit321.htm EX-32.1 5242
5 EXHIBIT 32.2 a06302017rasnaexhibit322.htm EX-32.2 5280
  Complete submission text file 0001628280-17-008478.txt   3562605

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rasp-20170630.xml EX-101.INS 642686
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rasp-20170630.xsd EX-101.SCH 32872
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rasp-20170630_cal.xml EX-101.CAL 39756
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rasp-20170630_def.xml EX-101.DEF 141366
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rasp-20170630_lab.xml EX-101.LAB 429241
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rasp-20170630_pre.xml EX-101.PRE 245587
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

EIN.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 171018899
SIC: 2834 Pharmaceutical Preparations